Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free VLG Stock Alerts

Venture Life Group (VLG) Competitors

Venture Life Group logo
GBX 69.48 -0.02 (-0.03%)
As of 06:12 AM Eastern
Compare

VLG vs. ANCR, BXP, STX, EAH, and DNL

Should you buy Venture Life Group stock or one of its competitors? MarketBeat compares Venture Life Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venture Life Group include Animalcare Group (ANCR), Beximco Pharmaceuticals (BXP), Shield Therapeutics (STX), ECO Animal Health Group (EAH), and Diurnal Group (DNL). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Venture Life Group compare to Animalcare Group?

Animalcare Group (LON:ANCR) and Venture Life Group (LON:VLG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Animalcare Group has higher revenue and earnings than Venture Life Group. Venture Life Group is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Animalcare Group£89.11M2.58£36.55M£7.3045.65
Venture Life Group£35.17M2.40£747.21K£4.3715.90

14.3% of Animalcare Group shares are owned by institutional investors. Comparatively, 21.9% of Venture Life Group shares are owned by institutional investors. 30.1% of Animalcare Group shares are owned by company insiders. Comparatively, 7.5% of Venture Life Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Venture Life Group has a net margin of 17.42% compared to Animalcare Group's net margin of 5.70%. Venture Life Group's return on equity of 7.82% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Animalcare Group5.70% 4.46% 2.97%
Venture Life Group 17.42%7.82%1.56%

In the previous week, Animalcare Group had 1 more articles in the media than Venture Life Group. MarketBeat recorded 1 mentions for Animalcare Group and 0 mentions for Venture Life Group. Venture Life Group's average media sentiment score of 1.54 beat Animalcare Group's score of 0.67 indicating that Venture Life Group is being referred to more favorably in the news media.

Company Overall Sentiment
Animalcare Group Positive
Venture Life Group Very Positive

Animalcare Group has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.217, indicating that its stock price is 78% less volatile than the broader market.

Summary

Animalcare Group beats Venture Life Group on 9 of the 13 factors compared between the two stocks.

How does Venture Life Group compare to Beximco Pharmaceuticals?

Beximco Pharmaceuticals (LON:BXP) and Venture Life Group (LON:VLG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.9% of Venture Life Group shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Comparatively, 7.5% of Venture Life Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Venture Life Group. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03
Venture Life Group£35.17M2.40£747.21K£4.3715.90

Beximco Pharmaceuticals has a beta of 0.251, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.217, suggesting that its stock price is 78% less volatile than the broader market.

In the previous week, Venture Life Group's average media sentiment score of 1.54 beat Beximco Pharmaceuticals' score of 0.00 indicating that Venture Life Group is being referred to more favorably in the news media.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Venture Life Group Very Positive

Venture Life Group has a net margin of 17.42% compared to Beximco Pharmaceuticals' net margin of 16.76%. Beximco Pharmaceuticals' return on equity of 11.99% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Venture Life Group 17.42%7.82%1.56%

Summary

Beximco Pharmaceuticals and Venture Life Group tied by winning 6 of the 12 factors compared between the two stocks.

How does Venture Life Group compare to Shield Therapeutics?

Venture Life Group (LON:VLG) and Shield Therapeutics (LON:STX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Venture Life Group has a beta of 0.217, meaning that its share price is 78% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 140.77%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than Venture Life Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Venture Life Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

21.9% of Venture Life Group shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Venture Life Group has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.40£747.21K£4.3715.90
Shield Therapeutics£49.70M1.34-£36.28M-£2.00N/A

In the previous week, Venture Life Group's average media sentiment score of 1.54 beat Shield Therapeutics' score of 0.00 indicating that Venture Life Group is being referred to more favorably in the media.

Company Overall Sentiment
Venture Life Group Very Positive
Shield Therapeutics Neutral

Venture Life Group has a net margin of 17.42% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Shield Therapeutics -35.72%121.87%-47.85%

Summary

Venture Life Group beats Shield Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Venture Life Group compare to ECO Animal Health Group?

Venture Life Group (LON:VLG) and ECO Animal Health Group (LON:EAH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, ECO Animal Health Group had 3 more articles in the media than Venture Life Group. MarketBeat recorded 3 mentions for ECO Animal Health Group and 0 mentions for Venture Life Group. ECO Animal Health Group's average media sentiment score of 1.69 beat Venture Life Group's score of 1.54 indicating that ECO Animal Health Group is being referred to more favorably in the news media.

Company Overall Sentiment
Venture Life Group Very Positive
ECO Animal Health Group Very Positive

Venture Life Group has a net margin of 17.42% compared to ECO Animal Health Group's net margin of 2.50%. Venture Life Group's return on equity of 7.82% beat ECO Animal Health Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
ECO Animal Health Group 2.50%2.55%2.14%

ECO Animal Health Group has higher revenue and earnings than Venture Life Group. Venture Life Group is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.40£747.21K£4.3715.90
ECO Animal Health Group£85.81M0.69£1.05M£4.3920.05

ECO Animal Health Group has a consensus target price of GBX 160, suggesting a potential upside of 81.82%. Given ECO Animal Health Group's stronger consensus rating and higher probable upside, analysts clearly believe ECO Animal Health Group is more favorable than Venture Life Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Venture Life Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ECO Animal Health Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

21.9% of Venture Life Group shares are held by institutional investors. Comparatively, 40.8% of ECO Animal Health Group shares are held by institutional investors. 7.5% of Venture Life Group shares are held by insiders. Comparatively, 11.2% of ECO Animal Health Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Venture Life Group has a beta of 0.217, indicating that its stock price is 78% less volatile than the broader market. Comparatively, ECO Animal Health Group has a beta of 0.004, indicating that its stock price is 100% less volatile than the broader market.

Summary

ECO Animal Health Group beats Venture Life Group on 12 of the 16 factors compared between the two stocks.

How does Venture Life Group compare to Diurnal Group?

Diurnal Group (LON:DNL) and Venture Life Group (LON:VLG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

In the previous week, Venture Life Group's average media sentiment score of 1.54 beat Diurnal Group's score of 0.00 indicating that Venture Life Group is being referred to more favorably in the news media.

Company Overall Sentiment
Diurnal Group Neutral
Venture Life Group Very Positive

Venture Life Group has a net margin of 17.42% compared to Diurnal Group's net margin of 0.00%. Venture Life Group's return on equity of 7.82% beat Diurnal Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Diurnal GroupN/A N/A N/A
Venture Life Group 17.42%7.82%1.56%

21.9% of Venture Life Group shares are held by institutional investors. 7.5% of Venture Life Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Venture Life Group has higher revenue and earnings than Diurnal Group. Diurnal Group is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diurnal Group£4.68M0.00N/A-£8.50N/A
Venture Life Group£35.17M2.40£747.21K£4.3715.90

Summary

Venture Life Group beats Diurnal Group on 9 of the 9 factors compared between the two stocks.

Get Venture Life Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VLG vs. The Competition

Export
MetricVenture Life GroupDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£84.29M£5.83B£6.96B£2.77B
Dividend Yield0.09%2.82%2.68%6.12%
P/E Ratio15.905.0527.20368.14
Price / Sales2.401,652.92578.1384,676.43
Price / Cash6.4010.1849.2527.89
Price / Book1.1810.6110.747.50
Net Income£747.21K£20.27B£3.59B£5.89B
7 Day Performance4.49%-0.15%-1.92%-0.04%
1 Month Performance4.95%-0.31%2.23%-1.39%
1 Year Performance24.07%7.89%23.82%61.97%

Venture Life Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VLG
Venture Life Group
N/AGBX 69.48
0.0%		N/A+21.4%£84.29M£35.17M15.90165
ANCR
Animalcare Group
N/AGBX 332
flat		N/A+19.1%£229.23M£89.11M45.48220
BXP
Beximco Pharmaceuticals
N/AGBX 50
-2.6%		N/A+35.0%£223.06M£53.93B0.035,500
STX
Shield Therapeutics
1.232 of 5 stars		GBX 6.45
-0.2%		GBX 15
+132.6%		+70.7%£68.98M£49.70MN/A40,000
EAH
ECO Animal Health Group
4.2843 of 5 stars		GBX 89
+1.1%		GBX 160
+79.8%		+13.3%£59.71M£85.81M20.27234

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:VLG) was last updated on 7/17/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel